Research programme: DNA oligonucleotides - Liminal BioSciences
Alternative Names: BT 99-25; DNA oligonucleotides research programme - TelestaLatest Information Update: 14 Oct 2019
At a glance
- Originator Bioniche Life Sciences
- Developer Liminal BioSciences
- Class Oligonucleotides
- Mechanism of Action Apoptosis stimulants; Immunostimulants; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Leukaemia
Most Recent Events
- 03 Oct 2019 Prometic Life Sciences is now called Liminal BioSciences
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Canada
- 04 Nov 2017 No recent reports of development identified for preclinical development in Leukaemia in Canada